KURT SARTORIUS^1,2,3,*, BENN SARTORIUS⁴, CHERIE WINKLER⁵, ANIL CHUTURGOON², ANNA KRAMVIS¹, PING AN⁵, WEIGANG ZHANG⁶, YUNJIE LU^3,6,7,*

BIOCELL, Vol.48, No.11, pp. 1543-1567, 2024, DOI:10.32604/biocell.2024.055505 - 07 November 2024

Abstract Hepatitis B-associated hepatocellular carcinoma (HBV-HCC) remains an intractable high-mortality solid tumor cancer that accounted for 42% of global HCC cases in 2019. Despite some developments in systemic therapy, only a small subset of late-stage HCC patients responds positively to recently developed therapeutic innovations. MicroRNAs (miRNAs) act as an ancillary epigenetic system that can regulate genome expression in all cancer pathways including HCC. The molecular mechanisms of miRNA regulation in cancer pathogenesis offered researchers a new approach that was widely hoped would translate into miRNA-based drugs and diagnostics. Thirty years on, miRNA-based diagnostic and therapeutic agents… More >

POOJA YADAV, NAR SINGH CHAUHAN^*

BIOCELL, Vol.48, No.8, pp. 1127-1143, 2024, DOI:10.32604/biocell.2024.051318 - 02 August 2024

Abstract A diverse array of microbes in and on the human body constitute the microbiota. These micro-residents continuously interact with the human host through the language of metabolites to dictate the host’s physiology in health and illnesses. Any biotic and abiotic component ensuring a balanced host-microbiota interaction are potential microbiome therapeutic agents to overcome human diseases. Plant metabolites are continually being used to treat various illnesses. These metabolites target the host’s metabolic machinery and host-gut microbiota interactions to overcome human diseases. Despite the paramount therapeutic significance of the factors affecting host-microbiota interactions, a comprehensive overview of More > Graphic Abstract

HUAN GAO^1,2, JIE ZHANG¹, TONY G. KLEIJN^1,3,4, ZHAOYONG WU⁵, BING LIU^1,6, YUJIN MA⁶, BAOYUE DING^1,*, DONGFENG YIN^2,*

Oncology Research, Vol.32, No.4, pp. 769-784, 2024, DOI:10.32604/or.2023.044276 - 20 March 2024

Abstract Bone metastasis secondary to breast cancer negatively impacts patient quality of life and survival. The treatment of bone metastases is challenging since many anticancer drugs are not effectively delivered to the bone to exert a therapeutic effect. To improve the treatment efficacy, we developed Pluronic P123 (P123)-based polymeric micelles dually decorated with alendronate (ALN) and cancer-specific phage protein DMPGTVLP (DP-8) for targeted drug delivery to breast cancer bone metastases. Doxorubicin (DOX) was selected as the anticancer drug and was encapsulated into the hydrophobic core of the micelles with a high drug loading capacity (3.44%). The… More > Graphic Abstract

VIGNESH BALAJI E¹, DIVYA RAMESH², MANISHA CHUNGAN SHAJU³, AKSHARA KUMAR⁴, SAMYAK PANDEY¹, RAKSHA NAYAK¹, V. ALKA⁵, SRISHTI MUNJAL⁶, AMIR SALIMI⁷, K. SREEDHARA RANGANATH PAI^1,*, SHANKAR M. BAKKANNAVAR²

Oncology Research, Vol.32, No.1, pp. 73-94, 2024, DOI:10.32604/or.2023.030401 - 15 November 2023

Abstract Exosomes, small tiny vesicle contains a large number of intracellular particles that employ to cause various diseases and prevent several pathological events as well in the human body. It is considered a “double-edged sword”, and depending on its biological source, the action of exosomes varies under physiological conditions. Also, the isolation and characterization of the exosomes should be performed accurately and the methodology also will vary depending on the exosome source. Moreover, the uptake of exosomes from the recipients’ cells is a vital and initial step for all the physiological actions. There are different mechanisms More > Graphic Abstract

RYAN STARK^*

BIOCELL, Vol.47, No.6, pp. 1191-1198, 2023, DOI:10.32604/biocell.2023.027838 - 19 May 2023

Abstract Protein-mediated interactions are the fundamental mechanism through which cells regulate health and disease. These interactions require physical contact between proteins and their respective targets of interest. These targets include not only other proteins but also nucleic acids and other important molecules as well. These proteins are often involved in multibody complexes that work dynamically to regulate cellular health and function. Various techniques have been adapted to study these important interactions, such as affinity-based assays, mass spectrometry, and fluorescent detection. The application of these techniques has led to a greater understanding of how protein interactions are More >

JIAWEI FU^1,2,3,#, CHUNSHUAI WU^1,2,3,#, GUANHUA XU^1,2,3, JINLONG ZHANG¹, YIQIU LI¹, CHUNYAN JI^1,2,3, ZHIMING CUI^1,2,3,*

BIOCELL, Vol.47, No.4, pp. 739-749, 2023, DOI:10.32604/biocell.2023.026881 - 08 March 2023

Abstract Spinal cord injury (SCI), a complex neurological disorder, triggers a series of devastating neuropathological events such as ischemia, oxidative stress, inflammatory events, neuronal apoptosis, and motor dysfunction. However, the classical necrosome, which consists of receptor-interacting protein (RIP)1, RIP3, and mixed-lineage kinase domain-like protein, is believed to control a novel type of programmed cell death called necroptosis, through tumour necrosis factor-alpha/tumour necrosis factor receptor-1 signalling or other stimuli. Several studies reported that necroptosis plays an important role in neural cell damage, release of intracellular pro-inflammatory factors, lysosomal dysfunction and endoplasmic reticulum stress. Recent research indicates that More >

RAHAT ALI¹, AFTAB ALAM², SATYENDRA K. RAJPUT³, RAZI AHMAD^4,*

BIOCELL, Vol.46, No.12, pp. 2681-2694, 2022, DOI:10.32604/biocell.2022.021224 - 10 August 2022

Abstract Parkinson’s disease (PD) is an age-related neurodegenerative ailment that affects dopamine-producing neurons in a specific area of the brain called the substantia nigra of the ventral midbrain. It is clinically characterized by movement disorder and marked with unusual synaptic protein alpha-synuclein accumulation in the brain. To date, only a few Food and Drug Administration (FDA) approved drugs are available on the market for the treatment of PD. Nonetheless, these drugs show parasympathomimetic related adverse events and remarkably higher toxicity; hence, it is important to find more efficacious molecules to treat PD. In our study, We… More >

ULVI BAYRAKTUTAN^*

BIOCELL, Vol.46, No.7, pp. 1593-1598, 2022, DOI:10.32604/biocell.2022.018679 - 17 March 2022

Abstract Ischaemic stroke is a debilitating disease with immense personal, societal and economic impact. Thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for this disease. As each year less than 1% of eligible patients receive this therapy worldwide, efficacious new therapeutics are desperately needed. Emerging evidence suggest endothelial progenitor cells (EPCs), capable of repairing damaged vasculature, as one such therapeutics. However, questions regarding their optimal dose, delivery route and in vivo survivability remain largely unanswered. Outgrowth endothelial cells, generated in large numbers by ex vivo expansion of EPCs, enable effective assessment of these More >

KAI WANG^2,#, FENGTIAN ZHANG^1,3,4,#, CHANGLONG WEN⁵, ZHIHUA HUANG⁶, ZHIHAO HU¹, YUWEN ZHANG¹, FUQIANG HU^2,*, LIJUAN WEN^1,6,*

Oncology Research, Vol.29, No.5, pp. 351-363, 2021, DOI:10.32604/or.2022.025696 - 10 October 2022

Abstract The blood-brain barrier (BBB) is an essential component in regulating and maintaining the homeostatic microenvironment of the central nervous system (CNS). During the occurrence and development of glioblastoma (GBM), BBB is pathologically destroyed with a marked increase in permeability. Due to the obstruction of the BBB, current strategies for GBM therapeutics still obtain a meager success rate and may lead to systemic toxicity. Moreover, chemotherapy could promote pathological BBB functional restoration, which results in significantly reduced intracerebral transport of therapeutic agents during multiple administrations of GBM and the eventual failure of GBM chemotherapy. The effective More >

FRANCESCO MAININI^*

BIOCELL, Vol.45, No.5, pp. 1171-1173, 2021, DOI:10.32604/biocell.2021.017399 - 12 July 2021

Abstract Adoptive cell therapy and Immune Checkpoint Blockade Inhibitors have recently revolutionized the field of oncology. However, these types of immunotherapeutic approaches have limited success in treating solid tumors. In particular, chimeric antigen receptor (CAR)-T cells efficacy is hampered by immunosuppressive signals in the tumor microenvironment (TME) and by a limited infiltration of re-infused T cells to the tumor site. The field of nanobiotechnology applied to oncology is also rapidly expanding. Nanoparticles-based delivery systems can be employed to modulate the activity of immune cells present in the TME enhancing the efficacy of CAR-T cells. Interestingly, nano-backpacks More >